View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 14, 2020

Exploring the hype around anti-malarial hydroxychloroquine

By Allie Nawrat

Hydroxychloroquine has attracted significant news coverage over the past two weeks as a potential treatment for Covid-19.

Approved to treat malaria and lupus, hydroxychloroquine has been heralded by US President Donald Trump as a very promising drug to fight Covid-19 or what he calls the ‘invisible enemy’ during his press briefings over the 4 and 5 April.

Trump’s remarks have baffled his scientific and medical advisors, most notably Dr Anthony Fauci, director of National Institute of Allergy and Infectious Diseases, who has repeatedly emphasised that the evidence supporting hydroxychloroquine is “anecdotal” at best.

Despite what President Trump may claim, it is crucial that this drug goes through clinical trials before it can be widely prescribed safely to Covid-19 patients.

Read the full article here.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU